US$ 28.12
glp 1 fda In a major milestone for obesity care, the has approved Wegovy® as the first oral GLP-1 receptor agonist for chronic weight management in adults with obesity or overweight and related conditions FDA Approves Oral Semaglutide as
Description
A New Era in Health?

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinsons disease, finds a new study led by UCL researchers.

99%+ purity
Weight support*

Click here to see which areas are affected.